Neuren Pharmaceuticals (OTCMKTS:NURPF) Shares Down 3.6% – Here’s What Happened

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF)’s share price was down 3.6% during trading on Tuesday . The stock traded as low as C$8.22 and last traded at C$8.22. Approximately 100 shares were traded during trading, a decline of 89% from the average daily volume of 875 shares. The stock had previously closed at C$8.53.

Neuren Pharmaceuticals Stock Down 3.6%

The stock’s 50 day moving average is C$10.56 and its two-hundred day moving average is C$12.01.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.